WallStSmart

AbbVie Inc (ABBV)vsThe Travelers Companies Inc (TRV)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AbbVie Inc generates 25% more annual revenue ($61.16B vs $48.83B). TRV leads profitability with a 12.9% profit margin vs 6.9%. ABBV appears more attractively valued with a PEG of 0.49. TRV earns a higher WallStSmart Score of 71/100 (B).

ABBV

Buy

63

out of 100

Grade: C+

Growth: 4.0Profit: 8.0Value: 4.7Quality: 5.0
Piotroski: 5/9Altman Z: 0.39

TRV

Strong Buy

71

out of 100

Grade: B

Growth: 6.0Profit: 7.5Value: 10.0Quality: 5.0
Piotroski: 4/9Altman Z: 0.65
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABBVSignificantly Overvalued (-1190.8%)

Margin of Safety

-1190.8%

Fair Value

$16.05

Current Price

$207.18

$191.13 premium

UndervaluedFair: $16.05Overvalued
TRVUndervalued (+75.4%)

Margin of Safety

+75.4%

Fair Value

$1213.50

Current Price

$290.59

$922.91 discount

UndervaluedFair: $1213.50Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABBV6 strengths · Avg: 9.7/10
Market CapQuality
$362.83B10/10

Mega-cap, among the largest globally

PEG RatioValuation
0.4910/10

Growing faster than its price suggests

Return on EquityProfitability
62.3%10/10

Every $100 of equity generates 62 in profit

Operating MarginProfitability
34.1%10/10

Strong operational efficiency at 34.1%

Debt/EquityHealth
-21.0610/10

Conservative balance sheet, low leverage

Free Cash FlowQuality
$4.89B8/10

Generating 4.9B in free cash flow

TRV6 strengths · Avg: 8.8/10
P/E RatioValuation
10.7x10/10

Attractively priced relative to earnings

Market CapQuality
$65.36B9/10

Large-cap with strong market position

Return on EquityProfitability
20.7%9/10

Every $100 of equity generates 21 in profit

Debt/EquityHealth
0.289/10

Conservative balance sheet, low leverage

Price/BookValuation
1.9x8/10

Reasonable price relative to book value

Operating MarginProfitability
25.9%8/10

Strong operational efficiency at 25.9%

Areas to Watch

ABBV4 concerns · Avg: 2.3/10
Profit MarginProfitability
6.9%3/10

6.9% margin — thin

P/E RatioValuation
87.0x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-88.7%2/10

Earnings declined 88.7%

Altman Z-ScoreHealth
0.392/10

Distress zone — elevated risk

TRV4 concerns · Avg: 3.0/10
PEG RatioValuation
2.364/10

Expensive relative to growth rate

Revenue GrowthGrowth
3.5%4/10

3.5% revenue growth

Free Cash FlowQuality
$02/10

Negative free cash flow — burning cash

Altman Z-ScoreHealth
0.652/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : ABBV

The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.49 suggests the stock is reasonably priced for its growth.

Bull Case : TRV

The strongest argument for TRV centers on P/E Ratio, Market Cap, Return on Equity.

Bear Case : ABBV

The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 87.0x leaves little room for execution misses.

Bear Case : TRV

The primary concerns for TRV are PEG Ratio, Revenue Growth, Free Cash Flow.

Key Dynamics to Monitor

TRV carries more volatility with a beta of 0.50 — expect wider price swings.

ABBV is growing revenue faster at 10.0% — sustainability is the question.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

TRV scores higher overall (71/100 vs 63/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AbbVie Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.

The Travelers Companies Inc

FINANCIAL SERVICES · INSURANCE - PROPERTY & CASUALTY · USA

The Travelers Companies, Inc., commonly known as Travelers, is an American insurance company.

Visit Website →

Want to dig deeper into these stocks?